Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NBTY Brand Mission Moves Into Personal Care Space

This article was originally published in The Tan Sheet

Executive Summary

NBTY purchases the Dr. Organic/Organic Doctor personal care line, continuing its focus on building its branded consumer business, especially internationally. The deal allows the firm to diversify its health and wellness portfolio and accelerate its entry to the mass market beauty and skin care category.

You may also be interested in...



CA Tries Again To Age-Restrict Workout Supplement Sales, MA On Energy Drinks

Massachusetts legislation proposes age-restricting energy drink sales and says violating parties will face fines between $50 and $250. California bill would prohibit sales of weight loss and workout products to minors, as is already proposed in New York and Massachusetts.

Bausch Shines Planned Spin-Out, Launches First US Preservative-Free OTC Antihistamine Eye Drops

Bausch + Lomb’s Alaway Preservative-Free antihistamine eye drops launch in US, The Bausch Health Companies division planned as spin-out also recently gained South Korean approval for its Lumify OTC redness reliever drops and has submissions under review in other countries.

US OTC Market In 2020: COVID-19 Impact Obvious In Medical Device As Well As Drug Sales Growth

Most notably among OTC drugs, hand sanitizer sales were up more than 600% to $1.46bn, while sales of consumer medical devices grew 15.6% to $14.8bn in 2020, according to CHPA report.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel